

Jim Doyle  
GovernorKaren E. Timberlake  
Secretary

## State of Wisconsin

Department of Health Services

Telephone: 608-266-8922  
FAX: 608-266-1096  
TTY: 888-692-1402  
dhfs.wisconsin.gov**MEDICAID PHARMACY PRIOR AUTHORIZATION ADVISORY COMMITTEE**  
**Recommendations Summary**  
**February 18, 2009****Pharmacy PA Testimony**

<b>Name</b>	<b>Company</b>	<b>Drug</b>	<b>Class</b>
Dr. David Tylicki		Anticonvulsants	Anticonvulsants
Dr. Romila Mushtaq	UCB-Group	Keppra XR	Anticonvulsants
Dr. George Morris		Anticonvulsants	Anticonvulsants
Dr. Brenda Dierschke		Lyrica	Anticonvulsants
Jane Meyer	Epilepsy Foundation	Anticonvulsants	Anticonvulsants
Beth Vanderheyden	Pfizer	Lyrica, Detrol LA, Lipitor, Caduet	Anticonvulsants
Dr. Jerome Lerner		Lyrica	Anticonvulsants
Angelica Munoz, Jeremiah Vinluan	Daichii Sankyo	Benicar,Azor	Angiotensin Modulators
Ndidi Yaucher	Novartin	Diovan,Tekturna	Angiotensin Modulators
Dr. Alfred Neuhoff	Forest Labs	Bystolic	Beta Blockers
Dr. Scott Conry	Merck/Schering Plough	Vytorin, Zetia	Lipotropics
Dr. David Gausso	Aurora Cardiovascular	Statins	Lipotropics
Dr. Thomas Fenske		Statins	Lipotropics
Dr. Ketul Patel	GlaxoSmithKline	Lovaza, Avandia	Lipotropics
Cianna Rigoni	Abbott	Lipotropics	Lipotropics
Dr. Donald J. Meyer		Simcor	Lipotropics
William Dozier	Gilead Sciences	PAH Agents	PAH Agents
Evette Brooks	Actelion	Tracleer	PAH Agents
Dr. Anthony Rieder	Alcon Labs	Ciprodex	Otic Fluoroquinolones

Scott Anderson/Annick Biat	Astra Zeneca	Nexium, Crestor	Proton Pump Inhibitors
Dr. M. Sethi		Bladders Relaxants	Bladders Relaxants
Bob Moreland	Astellas	Vesicare	Bladders Relaxants
Sheila Koszycki	Genzyme	Renagel/Renvela	Phosphates Binders
Steven Woods	Shire	Fosrenol	Phosphates Binders
Kaysen Bala	Novo Nordisk	Norditropin	Growth Hormone
Rose Mullen	Eli Lilly	Humantrope	Growth Hormone
Sanja Dragnic	EMD Serono	Saizen, Rebif	Growth Hormone
Aaron Davis	Genentech	Nutropin	Growth Hormone
Ann Joseph	Sandoz	Omnitrope	Growth Hormone
Linda Piccinini	Biogenidec	Avonex	Multiple Sclerosis
Janice Riga	Schering Plough	PegIntron	Hepatitis C
Ernst Pitting	Roche	Pegasys	Hepatitis C
Maureen Kubacki	Ortho Biotech	Procrit	Erythropoiesis Stimulating Hormones
Sanjay Mehta, Michael Masamitsu	Amgen	Epogen	Erythropoiesis Stimulating Hormones
Dr. Allan Rifkin		Migraine Medications	Antimigraine Triptans

**Approval of the minutes:**

- Motion to approve by Lawrence Fleming, M.D.
- Second by James Boblin, M.D.
- All in favor: **Motion passed**

**In Attendance:**

**Committee Member**

Rosanne Barber  
James Boblin, M.D.  
Catherine A. Decker, PharmD  
Anthony DeFranco, M.D., FACC  
Bradley Fedderly, M.D.

Lawrence Fleming, M.D.  
 Shel Gross  
 Kevin Izard, M.D.  
 Steve Maike, RPh  
 Pat Towers  
 Alicia Walker, PharmD  
 Michael Witkovsky, M.D.

**Roll Call Vote to go into Closed Session:**

Kevin Izard, M.D. made a motion to go into closed session.  
 Michael Witkovsky, M.D. seconded the motion.

<b>Committee Member</b>	<b>Vote for Closed Session</b>
Rosanne Barber	Aye
James Boblin, M.D.	Aye
Catherine A. Decker, PharmD	Aye
Anthony DeFranco, M.D., FACC	Aye
Bradley Fedderly, M.D.	Aye
Lawrence Fleming, M.D.	Aye
Shel Gross	Aye
Kevin Izard, M.D.	Aye
Steve Maike, RPh	Aye
Pat Towers	Aye
Alicia Walker, PharmD	Aye
Michael Witkovsky, M.D.	Aye

**Vote to go into Open Session:**

Pat Towers made a motion to return to open session.  
 Kevin Izard, M.D. seconded the motion.  
 All in favor, motion passed.

<i>1. Anticonvulsants (Seizure Disorders)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
DEPAKOTE (ORAL)	2.6%	ON	Yes		
CELONTIN (ORAL)	0.0%	ON	Yes		
PHENOBARBITAL (ORAL)	2.0%	ON	Yes-Generic		
CLONAZEPAM (ORAL)	18.1%	ON	Yes-Generic		
CARBAMAZEPINE (ORAL)	3.4%	ON	Yes-Generic		
GABAPENTIN (ORAL)	17.6%	ON	Yes-Generic		
DIVALPROEX (ORAL)	2.3%	ON	Yes-Generic		

## 1. Anticonvulsants (Seizure Disorders)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
VALPROIC ACID (ORAL)	1.2%	ON	Yes-Generic		
ZONISAMIDE (ORAL)	1.2%	ON	Yes-Generic		
PRIMIDONE (ORAL)	1.1%	ON	Yes-Generic		
PHENYTOIN (ORAL)	3.3%	ON	Yes-Generic		
PHENYTEK (ORAL)	0.1%	OFF	No		
CARBATROL (ORAL)	1.5%	ON	Yes		
TEGRETOL XR (ORAL)	1.0%	OFF	No		
PEGANONE (ORAL)	0.0%	ON	Yes		
DEPAKOTE SPRINKLE (ORAL)	1.7%	ON	Yes		
MEPHOBARBITAL (ORAL)	0.0%	ON	Yes-Generic		
LAMICTAL (ORAL)	10.4%	ON	Yes		
ETHOSUXIMIDE (ORAL)	0.2%	ON	Yes-Generic		
EQUETRO (ORAL)	0.0%	ON	Yes		
GABITRIL (ORAL)	0.2%	ON	Yes		
DEPAKOTE ER (ORAL)	6.9%	ON	Yes		
FELBATOL (ORAL)	0.6%	ON	Yes		
LYRICA (ORAL)	6.9%	ON	Yes		
KEPPRA SOLUTION (ORAL)	1.2%	ON	Yes		
TRILEPTAL SUSPENSION	0.5%	ON	Yes		
OXCARBAZEPINE (ORAL)	2.6%	ON	Yes-Generic		
KEPPRA XR (ORAL)	0.0%	OFF	Yes		
TOPAMAX (ORAL)	8.4%	ON	Yes		
STAVZOR (ORAL)	0.0%	OFF	No		
KEPPRA TABLETS (ORAL)	0.8%	ON	Yes		
LEVETIRACETAM TABLETS (ORAL)	0.0%	ON	Yes-Generic		
LAMOTRIGINE (ORAL)	3.5%	OFF	No-Generic		
DIASTAT (RECTAL)	0.6%	ON	Yes		

- Dr Kevin Izard made a motion to approve the recommendations.
  - Second - James Boblin
  - All in favor (10 members), Alicia Walker, and Bradley Fedderly were not in the room for the discussion or vote.
  - **Motion passed**

## 2. Sedative Hypnotics (Insomnia)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
RESTORIL 7.5 MG (ORAL)	0.2%	OFF	No		
FLURAZEPAM (ORAL)	1.1%	ON	Yes-Generic		
ZOLPIDEM (ORAL)	66.0%	ON	Yes-Generic		
TEMAZEPAM (ORAL)	17.2%	ON	Yes-Generic		
TRIAZOLAM (ORAL)	1.1%	OFF	No-Generic		
ESTAZOLAM (ORAL)	0.5%	ON	Yes-Generic		
CHLORAL HYDRATE (ORAL)	0.4%	ON	Yes-Generic		
ZALEPLON (ORAL)	0.2%	OFF	No-Generic		
DORAL (ORAL)	0.0%	OFF	No		
AMBIEN CR (ORAL)	4.9%	OFF	No		
ROZEREM (ORAL)	4.1%	ON	Yes		
LUNESTA (ORAL)	4.4%	OFF	No		

- Pat Towers made a motion to approve the recommendations.
  - Second - James Boblin
  - All in favor (10 members), Alicia Walker, and Bradley Fedderly were not in the room for discussion or for the vote.
  - **Motion passed**

<i>3. Angiotensin Modulators (High Blood Pressure)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
CAPTOPRIL / HCTZ (ORAL)	1.2%	ON	Yes-Generic		
ENALAPRIL / HCTZ (ORAL)	9.9%	ON	Yes-Generic		
LISINAPRIL / HCTZ (ORAL)	45.1%	ON	Yes-Generic		
BENZAEPRIIL / HCTZ (ORAL)	4.1%	ON	Yes-Generic		
ACEON (ORAL)	0.0%	OFF	Yes		
QUINAPRIL / HCTZ (ORAL)	0.6%	OFF	Yes-Generic		
FOSINPRIL / HCTZ (ORAL)	1.5%	ON	Yes-Generic		
TRANDOLAPRIL (ORAL)	0.2%	OFF	No-Generic		
DIOVAN / DIOVAN HCT	16.5%	ON	Yes		
AVAPRO / AVALIDE (ORAL)	2.7%	ON	Yes		
BENICAR / BENICAR HCT (ORAL)	4.2%	ON	Yes		
RAMIPRIL (ORAL)	0.5%	OFF	No-Generic		
MOEXIPRIL / HCTZ (ORAL)	0.1%	OFF	No-Generic		
COZAAR / HYZAAR (ORAL)	9.4%	ON	Yes		
MICARDIS / MICARDIS HCT (ORAL)	1.3%	ON	Yes		

### 3. Angiotensin Modulators (High Blood Pressure)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
ATACAND / ATACAND HCT (ORAL)	0.4%	OFF	No		
TEKTURN / TEKTURN HCT (ORAL)	0.2%	OFF	No		
TEVETEN / TEVETEN HCT (ORAL)	0.0%	OFF	No		

*DERP report from Mike Mergener: Cough varies with different ACE inhibitors. Cough from one ACE Inhibitor doesn't mean you will have cough with a different ACE Inhibitor.*

- The Committee made a motion to approve the recommendations:
  - Motion – Anthony DeFranco
  - Second - Kevin Izard
  - 11 members in favor
  - 1 member Alicia Walker, nay
  - **Motion passed**

### 4. Angiotensin Modulators/CCB Combinations (High Blood Pressure)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
EXFORGE (ORAL)	6.6%	ON	Yes		
AZOR (ORAL)	0.7%	OFF	Yes		
TARKA (ORAL)	3.2%	ON	Yes		
AMLODIPINE / BENAZEPRIL (ORAL)	75.1%	ON	No-Generic		

- Dr Lawrence Fleming made a motion to approve the recommendations.
  - Second - Anthony DeFranco
  - All in favor
  - **Motion passed**

### 5. Anticoagulants, Injectable (Clot Prevention)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
FRAGMIN (SUBCUTANE.)	5.9%	ON	Yes		
ARIXTRA (SUBCUTANE.)	3.2%	ON	Yes		
LOVENOX (SUBCUTANE.)	90.6%	ON	Yes		
INNOHEP (SUBCUTANE.)	0.3%	OFF	No		

- Dr Bradley Fedderly made a motion to approve the recommendations:

- Second - Alicia Walker
- All in favor
- **Motion passed**

<i>6. Beta-Blockers (High Blood Pressure and Heart Failure)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
ATENOLOL (ORAL)	28.4%	ON	Yes-Generic		
CARVEDILOL (ORAL)	8.8%	ON	Yes-Generic		
PINDOLOL (ORAL)	0.1%	ON	Yes-Generic		
NADOLOL (ORAL)	1.1%	ON	Yes-Generic		
ACEBUTOLOL (ORAL)	0.2%	ON	Yes-Generic		
METOPROLOL (ORAL)	50.9%	ON	Yes-Generic		
SOTALOL (ORAL)	0.9%	ON	Yes-Generic		
INNOPRAN XL (ORAL)	0.0%	OFF	No		
LABETALOL (ORAL)	2.2%	ON	Yes-Generic		
PROPRANOLOL (ORAL)	6.4%	ON	Yes-Generic		
TIMOLOL (ORAL)	0.0%	ON	Yes-Generic		
LEVATOL (ORAL)	0.0%	OFF	No		
BISOPROLOL (ORAL)	0.5%	ON	Yes-Generic		
BYSTOLIC (ORAL)	0.2%	OFF	No		
BETAXOLOL (ORAL)	0.0%	ON	No-Generic		
COREG CR (ORAL)	0.2%	OFF	No		

Alicia Walker, PharmD made a motion to modify the recommendations by adding Bystolic as preferred

- Second - Rosanne Barber
- **Aye** - Anthony DeFranco, Michael Witkovsky
- **Nay** - James Boblin, Catherine A. Decker , Bradley Fedderly, Lawrence Fleming, Shel Gross, Kevin Izard, Steve Maike, Pat Towers
- 4 members in favor
- 8 members in against
- **First Motion did not pass**

Dr Lawrence Fleming made a motion to approve the recommendations as presented.

- Second - Kevin Izard
- **Aye** - James Boblin, Catherine A. Decker , Bradley Fedderly, Lawrence Fleming, Shel Gross, Kevin Izard, Steve Maike, Pat Towers, Anthony DeFranco, Michael Witkovsky
- **Nay** - Rosanne Barber , Alicia Walker
- 10 members in favor
- 2 members in against

- **Second motion passed**

Steve Liles from Provider Synergies indicated that there is currently a shortage of the generic metoprolol succinate (Toprol XL). Both brand and generic will be preferred until shortage is over.

<i>7. Calcium Channel Blockers (High Blood Pressure)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
AMLODIPINE (ORAL)	60.5%	ON	Yes-Generic		
DYNACIRC CR (ORAL)	0.1%	OFF	Yes		
NICARDIPINE (ORAL)	0.1%	ON	Yes-Generic		
VERAPAMIL (ORAL)	8.0%	ON	Yes-Generic		
DILTIAZEM (ORAL)	19.4%	ON	Yes-Generic		
NIFEDIPINE IR (ORAL)	0.4%	ON	Yes-Generic		
SULAR (ORAL)	0.2%	OFF	No		
FELODIPINE ER (ORAL)	2.1%	ON	Yes-Generic		
NIFEDIPINE ER (ORAL)	7.9%	ON	Yes-Generic		
ISRADIPINE (ORAL)	0.1%	OFF	No-Generic		
VERAPAMIL ER PM (ORAL)	0.2%	ON	Yes		
COVERA-HS (ORAL)	0.0%	OFF	No		
CARDIZEM LA (ORAL)	0.9%	ON	No		
NISOLDIPINE (ORAL)	0.0%	OFF	No-Generic		
CARDENE SR (ORAL)	0.0%	OFF	No		
NIMODIPINE (ORAL)	0.0%	ON	Yes-Generic		

- Dr Bradley Fedderly made a motion to approve the recommendations.
  - Second - Anthony DeFranco
  - 12 members in favor
  - **Motion passed**

<i>8. Lipotropics, Other (High Cholesterol)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
NIACOR (ORAL)	0.0%	ON	Yes		
GEMFIBROZIL (ORAL)	26.8%	ON	Yes-Generic		
NIASPAN (ORAL)	19.6%	ON	Yes		
TRICOR (ORAL)	17.8%	ON	Yes		
CHOLESTYRAMINE (ORAL)	3.8%	ON	Yes-Generic		
FENOFIBRATE (ORAL)	7.2%	ON	Yes-Generic		

### 8. Lipotropics, Other (High Cholesterol)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
COLESTIPOL (ORAL)	0.8%	ON	Yes-Generic		
ZETIA (ORAL)	20.3%	ON	Yes		
LIPOFEN (ORAL)	0.0%	OFF	No		
ANTARA (ORAL)	0.2%	OFF	No		
LOVAZA (ORAL)	2.3%	OFF	No	Yes	
WELCHOL (ORAL)	1.2%	OFF	No		
FENOGLIDE (ORAL)	0.0%	OFF	No		
TRIGLIDE (ORAL)	0.0%	OFF	No		

- Motion – Dr. Kevin Izard made a motion to accept the current recommendations and add Lovaza as a preferred agent.
- Second - Bradley Fedderly
- 7 members in favor
- 5 members against
- **Aye** – Catherine A. Decker, Anthony DeFranco, Bradley Fedderly, Shel Gross, Kevin Izard, Steve Maike, Alicia Walker
- **Nay** - Rosanne Barber , James Boblin, Lawrence Fleming, Pat Towers, Michael Witkovsky
- **Motion passed**

### 9. Lipotropics, Statins (High Cholesterol)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
SIMVASTATIN (ORAL)	46.5%	ON	Yes-Generic		
PRAVASTATIN (ORAL)	3.8%	ON	Yes-Generic		
LOVASTATIN (ORAL)	12.9%	ON	Yes-Generic		
LESCOL / LESCOL XL	2.6%	ON	Yes		
ALTOPREV (ORAL)	0.0%	OFF	No		
SIMCOR (ORAL)	0.0%	OFF	Yes		
CRESTOR (ORAL)	3.7%	OFF	No		
LIPITOR (ORAL)	17.9%	ON	Yes		
VYTORIN (ORAL)	7.3%	ON	Yes		
CADUET (ORAL)	0.1%	OFF	No	Yes	
ADVICOR (ORAL)	0.1%	OFF	No		

- Dr James Boblin made a motion to accept the recommendations and add Caduet as a preferred agent.

- Second - Alicia Walker
- All in favor
- **Motion passed**

<i>10. PAH Agents, Oral (Pulmonary Arterial Hypertension)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
REVATIO (ORAL)	70.6%	NR	Yes		
LETAIRIS (ORAL)	7.0%	NR	Yes		
TRACLEER (ORAL)	22.4%	NR	No		

Pat Towers left the meeting at 3:30pm and was absent for the remaining votes.

Carrie Gray: Revatio is diagnosis restricted and has no quantity limits. The motion will include grandfathering members on Tracleer.

- Dr Anthony DeFranco made a motion to approve the recommendations.
  - Second - Bradley Fedderly
  - All in favor
  - **Motion passed**

<i>11. Otic Fluoroquinolones (Ear infections)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
FLOXIN (OTIC)	0.7%	ON	Yes		
OFLOXACIN (OTIC)	37.1%	ON	Yes-Generic		
CIPRODEX (OTIC)	61.6%	ON	Yes		
CIPRO HC (OTIC)	0.6%	OFF	No		

Michael Witkovsky was out of the room for this vote.

- Dr Kevin Izard made a motion to approve the recommendations.
  - Second - Catherine A. Decker
  - All in favor
  - **Motion passed**

<i>12. Antibiotics, GI (GI Infections)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
METRONIDAZOLE (ORAL)	92.7%	ON	Yes-Generic		

### 12. Antibiotics, GI (GI Infections)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
NEOMYCIN (ORAL)	1.1%	ON	Yes-Generic		
TINDAMAX (ORAL)	2.9%	ON	Yes		
FLAGYL ER (ORAL)	0.0%	OFF	No		
ALINIA (ORAL)	0.7%	ON	Yes		
XIFAXAN (ORAL)	1.1%	OFF	No		
VANOCIN HCL (ORAL)	1.5%	ON	Yes		

Michael Witkovsky was out of the room for this vote.

- Dr Lawrence Fleming made a motion to approve the recommendations.
  - Second - Steve Maike
  - All in favor
  - **Motion passed**

### 13. H. Pylori Treatment (H. Pylori)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
HELIDAC (ORAL)	6.4%	NR	Yes		
PREVPAC (ORAL)	82.7%	NR	No		
PYLERA (ORAL)	11.0%	NR	No		

- Dr Kevin Izard made a motion to approve the recommendations.
  - Second - Anthony DeFranco
  - All in favor
  - **Motion passed**

### 14. Proton Pump Inhibitors (Ulcers and Reflux)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
OMEPRAZOLE (ORAL)	2.6%	OFF	Yes-Generic		
OMEPRAZOLE OTC (ORAL)	0.1%	OFF	Yes-Generic		
PREVACID (ORAL)	28.1%	ON	Yes		
ACIPHEX (ORAL)	2.2%	OFF	No		
NEXIUM (ORAL)	46.3%	ON	No		
ZEGERID (ORAL)	0.1%	OFF	No		
PREVACID SOLUTAB (ORAL)	5.2%	ON	Yes		

*14. Proton Pump Inhibitors (Ulcers and Reflux)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
NEXIUM SUSPENSION (ORAL)	0.0%	ON	No		
PANTOPRAZOLE (ORAL)	0.4%	OFF	No-Generic		

- Dr. Kevin Izard made a motion to keep Nexium a preferred drug.
- There were no seconds.
- Motion did not pass.
  
- Dr Lawrence Fleming made a motion to approve the recommendations as presented.
  - Second - Bradley Fedderly
  - 10 Aye
  - 1 Nay—Kevin Izard
  - **Motion passed**

*15. Ulcerative Colitis Agents (Inflammation and sores of the intestine)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
SULFASALAZINE (ORAL)	31.4%	ON	Yes-Generic		
ASACOL (ORAL)	52.4%	ON	Yes		
DIPENTUM (ORAL)	0.4%	OFF	No		
PENTASA (ORAL)	8.1%	OFF	No		
LIALDA (ORAL)	1.8%	OFF	No		
BALSALAZIDE (ORAL)	2.9%	ON	Yes-Generic		
CANASA (RECTAL)	2.0%	ON	Yes		
MESALAMINE (RECTAL)	1.1%	ON	Yes-Generic		

- Dr James Boblin made a motion to approve the recommendations.
  - Second - Alicia Walker
  - All in favor
  - **Motion passed**

*16. Analgesics, Narcotics, Long-Acting (Pain)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
DURAGESIC (TRANSDERM.)	0.2%	OFF	Yes		
METHADONE (ORAL)	17.1%	ON	Yes-Generic		
MORPHINE ER (ORAL)	25.3%	ON	Yes-Generic		
KADIAN (ORAL)	5.7%	ON	Yes		

*16. Analgesics, Narcotics, Long-Acting (Pain)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
OPANA ER (ORAL)	0.4%	OFF	No		
AVINZA (ORAL)	0.3%	OFF	No		
ULTRAM ER (ORAL)	0.7%	OFF	No		
FENTANYL (TRANSDERM)	23.2%	ON	No-Generic		
OXYCONTIN (ORAL)	18.6%	OFF	Yes		
OXYCODONE ER (ORAL)	8.5%	ON	Yes-Generic		

- Dr Bradley Fedderly made a motion to approve the recommendations.
  - Second - James Boblin
  - All in favor
  - **Motion passed**

*17. Analgesics, Narcotics, Short-Acting (Pain)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
DARVON-N (ORAL)	0.0%	OFF	No		
APAP / CODEINE (ORAL)	9.7%	ON	Yes-Generic		
TRAMADOL (ORAL)	10.9%	ON	Yes-Generic		
PROPOXYPHENE / APAP (ORAL)	7.0%	ON	Yes-Generic		
ASA / CODEINE (ORAL)	0.0%	ON	Yes-Generic		
HYDROCODONE / APAP (ORAL)	47.7%	ON	Yes-Generic		
MORPHINE IR (ORAL)	0.8%	ON	Yes-Generic		
HYDROMORPHONE (ORAL)	0.5%	ON	Yes-Generic		
PROPOXYPHENE (ORAL)	0.3%	ON	Yes-Generic		
OXYCODONE / APAP (ORAL)	16.3%	ON	Yes-Generic		
OXYCODONE / IBUPROFEN (ORAL)	0.0%	ON	Yes-Generic		
OXYCODONE (ORAL)	5.7%	ON	Yes-Generic		
HYDROCODONE / IBUPROFEN (ORAL)	0.4%	ON	Yes-Generic		
TRAMADOL / APAP (ORAL)	0.1%	OFF	No-Generic		
MEPERIDINE (ORAL)	0.0%	OFF	No-Generic		
CODEINE (ORAL)	0.1%	ON	Yes-Generic		
PENTAZOCINE / NALOXONE (ORAL)	0.0%	OFF	No-Generic		
PENTAZOCINE / APAP (ORAL)	0.0%	OFF	No-Generic		
DIHYDROCODEINE / APAP / CAFFEINE (ORAL)	0.0%	ON	Yes-Generic		
OXYCODONE / ASA (ORAL)	0.0%	ON	Yes-Generic		
BUTALBITAL COMPOUND W/CODEINE (ORAL)	0.3%	ON	Yes-Generic	No	

<i>17. Analgesics, Narcotics, Short-Acting (Pain)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
OPANA (ORAL)	0.0%	OFF	No		
PANLOR DC (ORAL)	0.0%	OFF	No		
LEVORPHANOL (ORAL)	0.0%	ON	No-Generic		
FENTANYL (BUCCAL)	0.0%	OFF	No-Generic		
FENTORA (BUCCAL)	0.0%	OFF	No		

Dr James Boblin made a motion to make all butalbital products non-preferred and approve the remainder of the recommendations as presented.

Discussion: Rebound headaches occur when butalbital products are used to treat migraine and other headaches. Dr Boblin indicated he had not been to a headache seminar in 5 years where this issue has not come up. Every specialist wants butalbital off the market. It is not available in other countries

Kevin Izard: The motion to make all butalbital products non-preferred is broad. We may need a quantity limit instead. More people are addicted to Oxycontin. It is only a problem when people are taking an excessive amount, not people who take 30 tablets per month.

Alicia Walker: Remove all butalbital? I want to see more research to show that butalbital is not a good product.

Michael Witkovsky: Analgesic use, especially butalbital products, can cause withdrawal when not in your system.

- Second - Bradley Fedderly
- **Motion passed**

<i>18. Skeletal Muscle Relaxants (Spasticity and Muscle Relaxants)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
CYCLOBENZAPRINE (ORAL)	64.5%	ON	Yes-Generic		
CHLORZOXAZONE (ORAL)	1.0%	ON	Yes-Generic		
CARISOPRODOL (ORAL)	3.8%	OFF	No-Generic		
BACLOFEN (ORAL)	14.0%	ON	Yes-Generic		
METHOCARBAMOL (ORAL)	5.6%	ON	Yes-Generic		
TIZANIDINE (ORAL)	8.2%	ON	Yes-Generic		

*18. Skeletal Muscle Relaxants (Spasticity and Muscle Relaxants)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
SOMA 250 MG (ORAL)	0.1%	OFF	No		
CARISOPRODOL COMPOUND (ORAL)	0.0%	OFF	No-Generic		
ORPHENADRINE (ORAL)	0.3%	OFF	No-Generic		
ORPHENADRINE COMPOUND (ORAL)	0.0%	OFF	No-Generic		
SKELAXIN (ORAL)	1.5%	OFF	No		
FEXMID (ORAL)	0.0%	OFF	No		
DANTROLENE SODIUM (ORAL)	0.7%	ON	Yes-Generic		
ZANAFLEX CAPSULES (ORAL)	0.1%	OFF	No		
AMRIX (ORAL)	0.1%	OFF	No		

Discussion:

Alicia Walker: When carisoprodol was made non-preferred, what was the drop in utilization?

Carrie Gray. Market share dropped from 11%, to 3.8% when carisoprodol was made non-preferred.

- Dr Michael Witkovsky made a motion to approve the recommendations.
  - Second - Bradley Fedderly
  - All in favor
  - **Motion passed**

*19. Bladder Relaxant Preparations (Overactive Bladder)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
OXYBUTYNIN (ORAL)	24.3%	ON	Yes-Generic		
SANCTURA (ORAL)	2.4%	ON	No		
SANCTURA XR (ORAL)	0.9%	ON	No		
VESICARE (ORAL)	17.8%	ON	Yes		
OXYTROL (TRANSDERM.)	1.7%	ON	Yes		
DETROL LA (ORAL)	18.3%	ON	Yes		
ENABLEX (ORAL)	11.5%	ON	No		
DETROL (ORAL)	0.8%	OFF	No		
OXYBUTYNIN ER (ORAL)	12.6%	ON	No-Generic		

- Dr Lawrence Fleming made a motion to approve the recommendations:

- Second - James Boblin
- All in favor
- **Motion passed**

<i>20. BPH Treatments (Enlargement of the prostate)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
DOXAZOSIN (ORAL)	24.4%	ON	Yes-Generic		
TERAZOSIN (ORAL)	12.9%	ON	Yes-Generic		
PROSCAR (ORAL)	0.0%	ON	Yes		
CARDURA XL (ORAL)	0.0%	OFF	No		
UROXATRAL (ORAL)	2.8%	ON	Yes		
FINASTERIDE (ORAL)	8.3%	ON	Yes-Generic		
AVODART (ORAL)	9.7%	ON	Yes		
FLOMAX (ORAL)	41.9%	ON	Yes		

- Dr Kevin Izard made a motion to approve the recommendations.
  - Second - Catherine A. Decker
  - All in favor
  - **Motion passed**

<i>21. Hypoglycemics, Meglitinides (Type 2 Diabetes)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
PRANDIN (ORAL)	27.1%	OFF	Yes		
STARLIX (ORAL)	72.9%	ON	Yes		

- Dr Michael Witkovsky made a motion to approve the recommendations.
  - Second - Steve Maike
  - All in favor
  - **Motion passed**

<i>22. Hypoglycemics, TZDs (Type 2 Diabetes)</i>					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
ACTOS (ORAL)	71.8%	ON	Yes		
AVANDARYL (ORAL)	0.7%	ON	Yes		
AVANDIA (ORAL)	20.6%	ON	Yes		

*22. Hypoglycemics, TZDs (Type 2 Diabetes)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
DUETACT (ORAL)	0.3%	ON	Yes		
AVANDAMET (ORAL)	3.9%	ON	Yes		
ACTOPLUS MET (ORAL)	2.7%	ON	Yes		

- Dr Lawrence Fleming made a motion to approve the recommendations.
  - Second - Alicia Walker
  - All in favor
  - **Motion passed**

*23. Phosphate Binders (Removal of Phosphate in Kidney Disease)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
PHOSLO (ORAL)	39.8%	ON	Yes		
CALCIUM ACETATE (ORAL)	0.1%	ON	No-Generic		
RENAGEL (ORAL)	50.6%	ON	Yes		
FOSRENOL (ORAL)	8.1%	ON	Yes		
REVELA (ORAL)	1.4%	OFF	No		

- Dr Kevin Izard made a motion to approve the recommendations.
  - Second - Steve Maike
  - All in favor
  - **Motion passed**

*24. Erythropoiesis Stimulating Hormone (Treatment of low blood levels)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
ARANESP (INJECTION)	41.9%	ON	Yes		
PROCRIT (INJECTION)	57.0%	ON	Yes		
EPOGEN (INJECTION)	1.1%	OFF	No		

- Dr Lawrence Fleming made a motion to approve the recommendations.
  - Second - Bradley Fedderly
  - All in favor
  - **Motion passed**

### 25. Antimigraine Agents, Triptans (Migraines)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
FROVA (ORAL)	0.8%	OFF	No		
MAXALT / MAXALT MLT (ORAL)	21.3%	ON	Yes		
AXERT (ORAL)	1.1%	OFF	No		
RELPAX (ORAL)	8.8%	ON	Yes		
ZOMIG / ZOMIG ZMT (ORAL)	1.6%	OFF	No		
ZOMIG (NASAL)	0.2%	OFF	No		
AMERGE (ORAL)	0.7%	OFF	No		
TREXIMET (ORAL)	0.3%	OFF	No		
SUMATRIPTAN (NASAL)	0.0%	OFF	Yes-Generic		
SUMATRIPTAN (ORAL)	0.0%	ON	Yes-Generic		
SUMATRIPTAN (SUBCUTANE.)	0.0%	ON	Yes-Generic		

- Dr James Boblin made a motion to approve the recommendations
  - Second - Alicia Walker
  - All in favor
  - **Motion passed**

### 26. Antihistamines, Minimally Sedating (Allergies)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
LORATADINE / LORATADINE-D (ORAL)	54.0%	ON	Yes-Generic		
LORATADINE SYRUP (ORAL)	10.0%	ON	Yes-Generic		
CETIRIZINE / CETIRIZINE-D (ORAL)	21.1%	ON	Yes-Generic		
CETIRIZINE SYRUP (ORAL)	3.7%	ON	Yes-Generic		
CETIRIZINE SYRUP RX (ORAL)	0.9%	ON	Yes-Generic		
CLARITIN CHEW OTC (ORAL)	0.0%	OFF	No		
SEMPREX-D (ORAL)	0.0%	OFF	No		
ALLEGRA SYRUP (ORAL)	0.5%	OFF	No		
CLARINEX SYRUP (ORAL)	0.1%	OFF	No		
XYZAL (ORAL)	0.5%	OFF	No		
FEXOFENADINE (ORAL)	8.1%	OFF	No-Generic		
CLARINEX / CLARINEX-D (ORAL)	0.8%	OFF	No		
CETIRIZINE RX (ORAL)	0.0%	ON	No-Generic		
ALLEGRA ODT (ORAL)	0.0%	OFF	No		
XYZAL SYRUP (ORAL)	0.0%	OFF	No		

Discussion:

Catherine A. Decker: Will over-the-counter cetirizine still be covered even if the prescription cetirizine is made non-preferred?

Steve Liles: Correct, prescription cetirizine is much more expensive.

- Dr Lawrence Fleming made a motion to approve the recommendations.
  - Second - Catherine A. Decker
  - All in favor
  - **Motion passed**

27. Cough and Cold Products (Cough and Cold)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
PRO-CLEAR AC (ORAL)	0.0%	NR	No		
PRO-RED AC (ORAL)	0.0%	NR	No		
NARCOTIC ANTITUSSIVE / DECONGESTANT / EXPECTORANT GENERIC (ORAL)	56.9%	NR	Yes-Generic		
NARCOTIC ANTITUSSIVE / EXPECTORANT GENERIC (ORAL)	5.8%	NR	Yes-Generic		
M-END PE (ORAL)	0.0%	NR	No		
TUSNEL C (ORAL)	0.0%	NR	No		
NARCOTIC ANTITUSSIVE / ANTIHISTAMINE / DECONGESTANT GENERIC (ORAL)	2.7%	NR	Yes-Generic		
TUSSIONEX (ORAL)	27.7%	NR	No		
VANACOF CD (ORAL)	0.0%	NR	No		
NOTUSS AC / DC (ORAL)	0.0%	NR	No		
TUSNEL PED-C (ORAL)	0.0%	NR	No		
ALA-HIST AC (ORAL)	0.0%	NR	No		
ALAHIST DHC (ORAL)	0.0%	NR	No		
J-MAX DHC (ORAL)	0.0%	NR	No		
NARCOTIC ANTITUSSIVE / ANTICHOLINERGIC GENERIC (ORAL)	6.2%	NR	No-Generic		
ENDAL CD (ORAL)	0.0%	NR	No		
ZOTEX-C (ORAL)	0.0%	NR	No		
NALEX AC (ORAL)	0.0%	NR	No		
NUCOFED (ORAL)	0.0%	NR	No		
COTAB A / AX (ORAL)	0.0%	NR	No		
AMBIFED CD (ORAL)	0.0%	NR	No		
AMBIFED-G CD (ORAL)	0.0%	NR	No		
AMBIFED CDX (ORAL)	0.0%	NR	No		

27. Cough and Cold Products (Cough and Cold)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
AMBIFED-G CDX (ORAL)	0.0%	NR	No		
MAXIFED-G CDX (ORAL)	0.0%	NR	No		
MAXIFED-G CD (ORAL)	0.0%	NR	No		
MAXIFED CDX (ORAL)	0.0%	NR	No		
MAXIPHEN CDX (ORAL)	0.0%	NR	No		
MAXIFED CD (ORAL)	0.0%	NR	No		
MAXIPHEN CD (ORAL)	0.0%	NR	No		
TUSSICAPS (ORAL)	0.0%	NR	No		

**Lawrence Fleming: Absent for Vote, has left the meeting.**

Discussion:

Catherine A. Decker: This class, by law, can be dispensed without a prescription? Do over the counter (OTC) products require a prescription? Do these cough/cold products have quantity limits? Is there a reason not to apply quantity limits?

Alicia Walker: There are so many variations on this list. I don't know what many of these brands are or if they are generic. I want Tussionex to be preferred as it works and will not be made non-preferred easily.

Michael Witkovsky: This is needed for kids to get sleep, but probably not for adults. Are these schedule II products?

Steve Liles: There are frequent overdoses in kids under the age of 6 from OTC cough and cold products. There is not a good differentiation between brand or generic products. Each ingredient combination has its own class.

Carrie Gray: Medicaid requires a prescription for all federal legend and OTC products

- Dr Michael Witkovsky made a motion to approve the recommendations:
  - Second - James Boblin
  - Amendment from Alicia Walker to add Tussionex. Motion to amend fails.
  - 8 aye
  - 1 nay
  - **Motion passed**

28. Growth Hormone (Growth Deficiency)					
Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
OMNITROPE (INJECTION)	0.0%	OFF	No		

*28. Growth Hormone (Growth Deficiency)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
TEV-TROPIN (INJECTION)	2.5%	ON	No		
SAIZEN (INJECTION)	2.7%	ON	No		
NUTROPIN AQ (INJECTION)	12.4%	ON	Yes		
GENOTROPIN (INJECTION)	7.3%	ON	Yes		
NORDITROPIN (INJECTION)	2.4%	OFF	Yes		
NUTROPIN (INJECTION)	0.5%	ON	Yes		
SEROSTIM (INJECTION)	0.0%	OFF	No		
HUMATROPE (INJECTION)	0.1%	OFF	No		
ZORBTIVE (INJECTION)	0.0%	OFF	No		

- Dr Michael Witkovsky made a motion to approve the recommendations.
  - Second - James Boblin
  - All in favor
  - **Motion passed**

*29. Hepatitis C Agents (Hepatitis C)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
RIBAVIRIN (ORAL)	44.5%	ON	Yes-Generic		
PEGASYS (SUBCUTANE.)	26.2%	ON	Yes		
PEG-INTRON REDIPEN (SUBCUTANE.)	26.5%	ON	Yes		
PEG-INTRON (SUBCUTANE.)	2.0%	ON	Yes		
INFERGEN (SUBCUTANE.)	0.9%	OFF	No		

- Dr Bradley Fedderly made a motion to approve the recommendations.
  - Second - Catherine A. Decker
  - All in favor
  - **Motion passed**

*30. Multiple Sclerosis Agents (Multiple Sclerosis)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
BETASERON (SUBCUTANE.)	15.7%	ON	Yes		
COPAXONE (SUBCUTANE.)	38.3%	ON	Yes		

### 30. Multiple Sclerosis Agents (Multiple Sclerosis)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
AVONEX (INTRAMUSC.)	25.3%	ON	Yes		
REBIF (SUBCUTANE.)	20.8%	ON	Yes		

- Dr Michael Witkovsky made a motion to approve the recommendations.
  - Second - James Boblin
  - All in favor
  - **Motion passed**

### 31. Acne Agents, Topical (Acne)

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
AZELEX (TOPICAL)	1.6%	ON	Yes		
ERYTHROMYCIN (TOPICAL)	7.1%	ON	Yes-Generic		
CLINAC BPO (TOPICAL)	0.1%	ON	Yes		
CLINDAMYCIN PHOSPHATE (TOPICAL)	31.8%	ON	Yes-Generic		
BENZOYL PEROXIDE (TOPICAL)	25.5%	ON	Yes-Generic		
NUOX (TOPICAL)	0.0%	OFF	No		
RETIN-A MICRO (TOPICAL)	7.3%	ON	Yes		
TRETINOIN (TOPICAL)	17.4%	ON	Yes-Generic		
ZACLIR (TOPICAL)	0.0%	OFF	No		
LAVOCLEN (TOPICAL)	0.0%	OFF	No		
CLINDAGEL (TOPICAL)	0.1%	OFF	No		
DIFFERIN (TOPICAL)	2.6%	OFF	Yes		
SULFACETAMIDE / SULFUR (TOPICAL)	1.1%	ON	Yes-Generic		
AKNE-MYCIN (TOPICAL)	0.0%	OFF	No		
INOVA (TOPICAL)	0.0%	OFF	No		
BENZACLIN (TOPICAL)	1.5%	OFF	No		
TAZORAC (TOPICAL)	2.4%	ON	No		
ZACARE (TOPICAL)	0.0%	OFF	No		
ERYTHROMYCIN-BENZOYL PEROXIDE (TOPICAL)	0.9%	OFF	No-Generic		
BENZAMYCIN (TOPICAL)	0.1%	OFF	No		
CLARIFOAM EF (TOPICAL)	0.0%	OFF	No		
SULFACETAMIDE (TOPICAL)	0.1%	OFF	No-Generic		
DUAC (TOPICAL)	0.1%	OFF	No		
EVOCLIN (TOPICAL)	0.1%	OFF	No		
ATRALIN (TOPICAL)	0.0%	OFF	No		

*31. Acne Agents, Topical (Acne)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
ACZONE (TOPICAL)	0.0%	OFF	No		
ZIANA (TOPICAL)	0.0%	OFF	No		
NEOBENZ MICRO (TOPICAL)	0.0%	OFF	No		
CLINDAREACH (TOPICAL)	0.0%	OFF	No		

- Dr James Boblin made a motion to approve the recommendations.
  - Second - Bradley Fedderly
  - All in favor
  - **Motion passed**

*32. Impetigo Agents, Topical (Impetigo)*

Brand Name	Market Share	Current PDL Status	PDL Recommendation	Committee Modifications	Secretary Modifications
MUPIROCIN OINTMENT (TOPICAL)	98.3%	ON	Yes-Generic		
ALTABAX (TOPICAL)	1.0%	OFF	No		
BACTROBAN CREAM (TOPICAL)	0.6%	OFF	No		

- Dr Bradley Fedderly made a motion to approve the recommendations.
  - Second - Michael Witkovsky
  - All in favor
  - **Motion passed**

PH03006a